Connective Tissue Unit, Division of Metabolism and Children's Research Center, University Children's Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Front Endocrinol (Lausanne). 2023 May 25;14:1195704. doi: 10.3389/fendo.2023.1195704. eCollection 2023.
Osteogenesis imperfecta (OI) is a heritable and chronically debilitating skeletal dysplasia. Patients with OI typically present with reduced bone mass, tendency for recurrent fractures, short stature and bowing deformities of the long bones. Mutations causative of OI have been identified in over 20 genes involved in collagen folding, posttranslational modification and processing, and in bone mineralization and osteoblast development. In 2016, we described the first X-linked recessive form of OI caused by missense variants in patients with moderate to severe phenotypes. encodes site-2 protease, a Golgi transmembrane protein that activates membrane-tethered transcription factors. These transcription factors regulate genes involved in lipid metabolism, bone and cartilage development, and ER stress response. The interpretation of genetic variants in is complicated by the gene's pleiotropic properties; variants can also cause the dermatological conditions Ichthyosis Follicularis, Atrichia and Photophobia (IFAP), Keratosis Follicularis Spinulosa Decalvans (KFSD) and Olmsted syndrome (OS) without skeletal abnormalities typical of OI. Using control and patient-derived fibroblasts, we previously identified gene expression signatures that distinguish -OI from -IFAP/KFSD and observed stronger suppression of genes involved in fatty acid metabolism in -OI than in -IFAP/KFSD; this was coupled with alterations in the relative abundance of fatty acids in -OI. Furthermore, we observed a reduction in collagen deposition in the extracellular matrix by -OI fibroblasts. Here, we extrapolate our observations in the molecular signature unique to -OI to infer the pathogenicity of a novel c.516A>C (p.Glu172Asp) variant of unknown significance in a male proband. The pregnancy was terminated at gestational week 21 after ultrasound scans showed bowing of femurs and tibiae and shortening of long bones particularly of the lower extremity; these were further confirmed by autopsy. By performing transcriptional analyses, gas chromatography-tandem mass spectrometry-based quantification of fatty acids and immunocytochemistry on fibroblasts derived from the umbilical cord of the proband, we observed perturbations in fatty acid metabolism and collagen production similar to what we previously described in -OI. These findings support pathogenicity of the variant p.Glu172Asp as OI-causative and highlights the value of extrapolating molecular signatures identified in multiomics studies to characterize novel genetic variants.
成骨不全症(OI)是一种遗传性、慢性衰弱性骨骼发育不良。OI 患者通常表现为骨量减少、反复骨折、身材矮小和长骨弯曲畸形。OI 相关的致病突变已在 20 多个参与胶原折叠、翻译后修饰和加工以及骨矿化和成骨细胞发育的基因中被发现。2016 年,我们描述了首例由中重度表型患者的错义变异引起的 X 连锁隐性 OI 形式。 编码 II 型基质金属蛋白酶,一种高尔基膜蛋白,可激活膜结合转录因子。这些转录因子调节脂质代谢、骨骼和软骨发育以及内质网应激反应相关的基因。由于基因的多效性, 基因变异的解释变得复杂; 变异还可导致无 OI 典型骨骼异常的皮肤病,如滤泡性鱼鳞病、毛发稀少症和畏光症(IFAP)、毛囊角化性棘状脱发(KFSD)和 Olmsted 综合征(OS)。使用对照和患者来源的成纤维细胞,我们之前鉴定了可将 -OI 与 -IFAP/KFSD 区分开来的基因表达特征,并观察到 -OI 中脂肪酸代谢相关基因的抑制作用强于 -IFAP/KFSD;这与 -OI 中脂肪酸的相对丰度变化有关。此外,我们观察到 -OI 成纤维细胞的细胞外基质中胶原蛋白沉积减少。在这里,我们将我们在 -OI 特有的分子特征中的观察结果推断为一种新型 未知意义的 c.516A>C(p.Glu172Asp)变体在男性先证者中的致病性。在超声扫描显示股骨和胫骨弯曲以及下肢长骨缩短后,妊娠在妊娠 21 周终止;尸检进一步证实了这一点。通过进行转录分析、基于气相色谱-串联质谱的脂肪酸定量分析和先证者脐带衍生的成纤维细胞免疫细胞化学分析,我们观察到脂肪酸代谢和胶原蛋白产生的扰动与我们之前在 -OI 中描述的相似。这些发现支持 p.Glu172Asp 变体作为 OI 致病原因的致病性,并强调了从多组学研究中推断鉴定的分子特征来表征新型遗传变异的价值。